Discovery and characterization of a sophoridine-derived TNIK inhibitor with antitumor activity in hepatocellular carcinoma.
This work identifies YM17 as a potent sophoridine-derived TNIK inhibitor with cellular target engagement and in vivo anti-HCC activity and highlights the value of integrating phenotype-guided natural product scaffold diversification with proteome-scale target deconvolution for anticancer lead discovery.